Positions

Overview

  • Boni Elewski, M.D., an international leader in fungal and psoriasis research and dermatological clinical trials, was named the new chair of the University of Alabama at Birmingham Department of Dermatology in 2016.

    Elewski had been a professor of Dermatology at UAB for the past 17 years. She holds the James E. Elder M.D. Endowed Professorship for Graduate Education.

    Elewski is an international leader in fungal and psoriasis research and dermatological clinical trials. She’s been conducting clinical trials through her entire career and has received 85 clinical trial study grants to pursue therapies for many dermatologic conditions. She’s authored more than 300 publications and served in numerous national societies and organizations, including as president of the American Academy of Dermatology from 2004-2005.

    A part of the School of Medicine since its inception in 1945, the UAB Department of Dermatology has been one of the top academic departments of dermatology in the United States for over 70 years and includes 18 faculty, 13 residents and two fellows. The department provides comprehensive dermatological patient care, offering sophisticated services in the diagnosis and treatment of skin disease, and is a national center for the management of complicated skin disorders.

    An Ohio native, Elewski began her career at the Ohio State University College of Medicine, where she earned her medical degree before beginning an internship in internal medicine and residency in dermatology the University of North Carolina Memorial Hospital. She held faculty positions at the Northeastern Ohio University College of Medicine and the Case Western Reserve School of Medicine before joining the UAB faculty in 1999.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 Treatment of Tinea CapitisSkin Appendage Disorders2019
    2018 Single-Center, Prospective, Blinded Study Comparing the Efficacy and Compatibility of Efinaconazole 10% Solution in Treating Onychomycosis with and without Concurrent Nail Polish Use.Skin Appendage Disorders.  5:9-12. 2018
    2018 Subungual Space: The Next Frontier.Skin Appendage Disorders.  5:50-51. 2018
    2018 Ungual Horn.Skin Appendage Disorders.  5:56-59. 2018
    2018 Is Biotin Safe for Dermatology Patients?Skin Appendage Disorders.  4:201. 2018
    2018 A Phase 2, Controlled, Dose-Ranging Study of SB208, an Investigational Topical Nitric Oxide-Releasing Drug, for the Treatment of Tinea Pedis.Journal of Drugs in Dermatology.  17:888-893. 2018
    2018 Human polyomavirus-7-associated eruption successfully treated with acitretin.American Journal of Transplantation.  18:1278-1284. 2018
    2018 Image Gallery: Molluscum contagiosum-like facial lesions in a patient with a renal transplant: deep dermatophytosis due to Trichophyton rubrum.British Journal of Dermatology.  178:e328. 2018
    2018 Efinaconazole 10% Topical Solution: Case Review of Onychomycosis Patients Who Were Completely Cured at Week 24.Skin Appendage Disorders.  4:67-70. 2018
    2018 Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials.Journal of the European Academy of Dermatology and Venereology2018
    2018 Injection Site Necrosis and Ulceration Following Vaccination in an Adult Patient.Journal of Drugs in Dermatology.  17:364-367. 2018
    2018 Safety of secukinumab in hepatitis B virus.Journal of the European Academy of Dermatology and Venereology.  32:e120-e121. 2018
    2018 Is Severity of Disease a Prognostic Factor for Cure Following Treatment of Onychomycosis?Journal of Drugs in Dermatology.  17:175-178. 2018
    2018 Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial.Journal of The American Academy of Dermatology.  78:90-99.e1. 2018
    2018 Isolated Nail Dystrophy: An Unlikely Presentation of Metastatic Renal Cell CarcinomaSkin Appendage Disorders2018
    2017 Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab.Journal of Dermatological Treatment.  28:492-499. 2017
    2017 Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis.Journal of The American Academy of Dermatology.  77:79-87.e1. 2017
    2017 Cutaneous plasmacytosis resembling pityriasis rosea in a 66-year-old white woman: A rare disease presenting in an unusual patient demographic.JAAD Case Reports.  3:78-81. 2017
    2016 Optimizing Non-Antibiotic Treatments for Patients with Acne: A Review.Dermatology and Therapy.  6:555-578. 2016
    2016 Topical Treatment for Onychomycosis: Is it More Effective than the Clinical Data Suggests?The Journal of clinical and aesthetic dermatology.  9:34-39. 2016
    2016 Onychomycosis: Practical Approaches to Minimize Relapse and Recurrence.Skin Appendage Disorders.  2:83-87. 2016
    2016 Confirmatory Testing for Onychomycosis.JAMA Dermatology.  152:848. 2016
    2016 Response to "A financial perspective on the topical treatment of onychomycosis".Journal of The American Academy of Dermatology.  75:e39. 2016
    2016 Onychomycosis: Does Cure Equate to Treatment Success?Journal of Drugs in Dermatology.  15:626-632. 2016
    2016 Successful Treatment of Paecilomyces lilacinus Onychomycosis with Efinaconazole and Tavaborole.Skin Appendage Disorders.  1:169-171. 2016
    2016 Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials.International Journal of Dermatology.  55:401-407. 2016
    2016 Onychomycosis: Strategies to Minimize Recurrence.Journal of Drugs in Dermatology.  15:279-282. 2016
    2016 Psychometric validation of the Psoriasis Symptom Diary using Phase III study data from patients with chronic plaque psoriasis.International Journal of Dermatology.  55:e147-e155. 2016
    2016 Anti-IL-17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.American Journal of Clinical Dermatology.  17:33-47. 2016
    2016 Secukinumab (AIN-457) for the treatment of Psoriasis.Expert Review of Clinical Pharmacology.  9:187-202. 2016
    2015 Risk Factors and Comorbidities for Onychomycosis: Implications for Treatment with Topical Therapy.The Journal of clinical and aesthetic dermatology.  8:38-42. 2015
    2015 Identifying Signs of Tinea Pedis: A Key to Understanding Clinical VariablesJournal of Drugs in Dermatology.  14:s42-s47. 2015
    2015 Identifying Signs of Tinea Pedis: A Key to Understanding Clinical Variables.Journal of Drugs in Dermatology.  14:s42-s47. 2015
    2015 Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.British Journal of Dermatology.  173:949-961. 2015
    2015 Pulmonary Cryptococcosis in the Setting of Tofacitinib Therapy for Psoriasis.Journal of Drugs in Dermatology.  14:901-902. 2015
    2015 A phase 3 randomized, double-blind, vehicle-controlled trial of azelaic acid foam 15% in the treatment of papulopustular rosacea.Cutis.  96:54-61. 2015
    2015 Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies.Journal of The American Academy of Dermatology.  73:62-69. 2015
    2015 Report of a case of a dermatophytoma successfully treated with topical efinaconazole 10% solution.Journal of Drugs in Dermatology.  14:524-526. 2015
    2015 The ABCDEF Rule: Combining the "ABCDE Rule" and the "Ugly Duckling Sign" in an Effort to Improve Patient Self-Screening Examinations.The Journal of clinical and aesthetic dermatology.  8:15. 2015
    2015 Tanning accelerators: prevalence, predictors of use, and adverse effects.Journal of The American Academy of Dermatology.  72:99-104. 2015
    2014 Access of efinaconazole topical solution, 10%, to the infection site by spreading through the subungual space.Journal of Drugs in Dermatology.  13:1394-1398. 2014
    2014 Treatment of onychomycosis with efinaconazole 10% topical solution and quality of life.The Journal of clinical and aesthetic dermatology.  7:25-30. 2014
    2014 A randomized, double-blinded trial evaluating the efficacy and tolerability of vectical ointment (calcitriol 3 mcg/g ointment) when compared to betamethasone diproprionate ointment (64 mg/g) in patients with nail psoriasis.Journal of Drugs in Dermatology.  13:912-915. 2014
    2014 Secukinumab in plaque psoriasis--results of two phase 3 trials.New England Journal of Medicine.  371:326-338. 2014
    2014 Econazole nitrate foam 1% for the treatment of tinea pedis: results from two double-blind, vehicle-controlled, phase 3 clinical trials.Journal of Drugs in Dermatology.  13:803-808. 2014
    2014 Tavaborole for the treatment of onychomycosis.Expert Opinion on Pharmacotherapy.  15:1439-1448. 2014
    2014 The efficacy and safety of efinaconazole 10% solution for treatment of mild to moderate onychomycosis: a pooled analysis of two phase 3 randomized trials.Journal of Drugs in Dermatology.  13:815-820. 2014
    2014 Erratum: Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies(Journal of the American Academy of Dermatology (2013) 68 (600-8))Journal of The American Academy of Dermatology.  70:399. 2014
    2013 Treatment of nonmelanoma skin cancer.JAMA Internal Medicine.  173:2096-2097. 2013
    2013 Azelaic acid foam 15% in the treatment of papulopustular rosacea: a randomized, double-blind, vehicle-controlled study.Cutis.  92:306-317. 2013
    2013 Treatment of onychomycosis using a submillisecond 1064-nm neodymium:yttrium-aluminum-garnet laser.Journal of The American Academy of Dermatology.  69:578-582. 2013
    2013 Item-level psychometric properties for a new patient-reported psoriasis symptom diary.Value in Health.  16:1014-1022. 2013
    2013 Efinaconazole 10% solution: A new topical antifungal therapy for onychomycosisExpert Review of Dermatology.  8:347-356. 2013
    2013 Onchomycosis: an overview.Journal of Drugs in Dermatology.  12:s96-103. 2013
    2013 Current and emerging options in the treatment of onychomycosis.Seminars in Cutaneous Medicine and Surgery.  32:S9-12. 2013
    2013 Diagnosis, clinical implications, and complications of onychomycosis.Seminars in Cutaneous Medicine and Surgery.  32:S5-S8. 2013
    2013 Nail findings board reviewJournal of Drugs in Dermatology.  12:705-706. 2013
    2013 Onychomycosis information for patients.Seminars in Cutaneous Medicine and Surgery.  32:2p. following S9-12. 2013
    2013 Program spotlight: The University of Alabama at Birmingham Department of Dermatology Residency Training ProgramJournal of Drugs in Dermatology.  12:699-700. 2013
    2013 Promoting and maintaining or restoring healthy nails: practical recommendations for clinicians and patients.Seminars in Cutaneous Medicine and Surgery.  32:S13-S14. 2013
    2013 Resident Rounds. Part III B: tumor necrosis factor-α antagonists and alopecia areata: a class-wide adverse effect.Journal of Drugs in Dermatology.  12:713-714. 2013
    2013 The epidemiology, etiology, and pathophysiology of onychomycosis.Seminars in Cutaneous Medicine and Surgery.  32:S2-S4. 2013
    2013 Tumor necrosis factor-α antagonists and alopecia areata: A class-wide adverse effectJournal of Drugs in Dermatology.  12:713-714. 2013
    2013 Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies.Journal of The American Academy of Dermatology.  68:600-608. 2013
    2013 Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild-to-moderate toenail onychomycosis: results from three randomized studies using double-blind vehicle-controlled and open-label active-controlled designs.Journal of the European Academy of Dermatology and Venereology.  27:287-294. 2013
    2013 New side effect of TNF-alpha inhibitors: morphea.SKINmed.  11:59-60. 2013
    2013 Palmoplantar pustulosis with fulminant dystrophic 20-nail psoriasis in a patient receiving adalimumab therapy.Journal of Drugs in Dermatology.  12:16-17. 2013
    2012 Cosmetic aspects of nail products and servicesCosmetic Dermatology -Cedar Knolls-.  25:357-363. 2012
    2012 Sarcoidosis as an adverse effect of tumor necrosis factor inhibitors.Journal of Drugs in Dermatology.  11:609-612. 2012
    2012 A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis.British Journal of Dermatology.  166:389-398. 2012
    2011 A new classification system for grading the severity of onychomycosis: Onychomycosis Severity Index.Archives of Dermatology -Chicago-.  147:1277-1282. 2011
    2011 Recent updates in oral terbinafine: its use in onychomycosis and tinea capitis in the US.Mycoses.  54:e679-e685. 2011
    2011 Tinea capitis caused by dermatophytes: a 15-year retrospective study from a Mississippi Dermatology Clinic.Cutis.  88:230-233. 2011
    2011 An open-label study of the safety and efficacy of sertaconazole nitrate in the treatment of seborrheic dermatitis.Journal of Drugs in Dermatology.  10:895-899. 2011
    2011 Tinea capitis in Birmingham: survey of elementary school students.Pediatric Dermatology.  28:476-477. 2011
    2011 Interest in cosmetic improvement as a marker for tanning behavior: a survey of 1602 respondents.Journal of Cosmetic Dermatology.  10:3-10. 2011
    2011 Rosacea - global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group.Journal of the European Academy of Dermatology and Venereology.  25:188-200. 2011
    2011 Systemic drugs in patients with skin diseasesGiornale Italiano di Dermatologia e Venereologia.  146:397-424. 2011
    2010 Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.JNCI: Journal of the National Cancer Institute.  102:1835-1844. 2010
    2010 Wong type dermatomyositis: 20th case reported.Journal of Drugs in Dermatology.  9:1475-1476. 2010
    2010 Optimizing topical therapies for treating psoriasis: a consensus conference.Cutis.  86:5-31. 2010
    2010 Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study.Journal of Drugs in Dermatology.  9:928-937. 2010
    2010 Letters to the editorJournal of Drugs in Dermatology.  9:750. 2010
    2010 Naftifine, a topical allylamine.Journal of Drugs in Dermatology.  9:750. 2010
    2010 Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference.Journal of The American Academy of Dermatology.  62:838-853. 2010
    2010 Top-accessed article: White superficial onychomycosisArchives of Dermatology -Chicago-.  146:554. 2010
    2009 Rosacea: a review of current topical, systemic and light-based therapies.Giornale Italiano di Dermatologia e Venereologia.  144:673-688. 2009
    2009 An investigator-blind, randomized, 4-week, parallel-group, multicenter pilot study to compare the safety and efficacy of a nonsteroidal cream (Promiseb Topical Cream) and desonide cream 0.05% in the twice-daily treatment of mild to moderate seborrheic dermatitis of the face.Clinics in Dermatology.  27:S48-S53. 2009
    2009 Onychomycosis and diabetes.Journal of the European Academy of Dermatology and Venereology.  23:1119-1122. 2009
    2009 Safe and effective treatment of seborrheic dermatitis.Cutis.  83:333-338. 2009
    2009 Lack of classic histology should not prevent diagnosis of necrolytic acral erythema.Journal of The American Academy of Dermatology.  60:504-507. 2009
    2009 Results of a national rosacea patient survey: common issues that concern rosacea sufferers.Journal of Drugs in Dermatology.  8:120-123. 2009
    2009 Diclofenac sodium 3% gel as a potential treatment for disseminated superficial actinic porokeratosis.Journal of the European Academy of Dermatology and Venereology.  23:42-45. 2009
    2008 Infliximab for the treatment of severe pustular psoriasis: 6 years later.Journal of the European Academy of Dermatology and Venereology.  22:1253-1254. 2008
    2008 Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: results of two randomized, investigator-blinded, multicenter, international, controlled trials.Journal of The American Academy of Dermatology.  59:41-54. 2008
    2008 The safety and efficacy of high-dose alefacept compared with a loading dose of alefacept in patients with chronic plaque psoriasis.SKINmed.  7:67-72. 2008
    2008 The prevalence of acne in adults 20 years and older.Journal of The American Academy of Dermatology.  58:56-59. 2008
    2007 A novel foam formulation of ketoconazole 2% for the treatment of seborrheic dermatitis on multiple body regions.Journal of Drugs in Dermatology.  6:1001-1008. 2007
    2007 In reference to the October 2004 comprehensive overview of rosacea therapy.Journal of The American Academy of Dermatology.  57:728. 2007
    2007 Onychomycosis: diagnosis and definition of cure.Journal of The American Academy of Dermatology.  56:939-944. 2007
    2007 Advances in topical and systemic antifungals.Dermatologic Clinics.  25:165-vi. 2007
    2007 New opportunities in preventative dermatology: how far should we go?Journal of The American Academy of Dermatology.  56:675-676. 2007
    2007 Percutaneous absorption kinetics of topical metronidazole formulations in vitro in the human cadaver skin model.Advances in Therapy.  24:239-246. 2007
    2007 Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris.Journal of The American Academy of Dermatology.  56:439.e1-439.10. 2007
    2007 A new gel formulation of miconazole nitrate 2% for the treatment of chronic intertrigoCosmetic Dermatology -Cedar Knolls-.  20:43-44. 2007
    2007 Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis.British Journal of Dermatology.  156:138-142. 2007
    2007 Letter to the editorCutis.  79:57-58. 2007
    2007 Rosacea trial comparing twice-daily azelaic acid gel 15% with once-daily metronidazole gel 1%.Cutis.  79:57-58. 2007
    2006 Azelaic acid gel 15%: Clinical versatility in the treatment of rosaceaCutis.  78:6-19. 2006
    2006 Azelaic acid gel 15%: clinical versatility in the treatment of rosacea.Cutis.  78:6-19. 2006
    2006 Azelaic acid 15% gel for treatment of rosaceaExpert Review of Dermatology.  1:535-545. 2006
    2006 Efficacy and safety of a new once-daily topical ketoconazole 2% gel in the treatment of seborrheic dermatitis: a phase III trial.Journal of Drugs in Dermatology.  5:646-650. 2006
    2006 Alefacept in the treatment of psoriatic nail disease: a proof of concept study.Journal of Drugs in Dermatology.  5:339-340. 2006
    2006 Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial.Journal of The American Academy of Dermatology.  54:S112-S119. 2006
    2006 A clinical overview of azelaic acid.Cutis.  77:12-16. 2006
    2006 Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy.Journal of Dermatological Treatment.  17:9-17. 2006
    2006 Intermittent versus continuous terbinafine in the treatment of toenail onychomycosis: a randomized, double-blind comparison.Journal of Dermatological Treatment.  17:38-44. 2006
    2005 Clinical diagnosis of common scalp disorders.Journal of Investigative Dermatology Symposium Proceedings.  10:190-193. 2005
    2005 A bipartite interaction between Pseudomonas aeruginosa and fungi in onychomycosis.Archives of Dermatology -Chicago-.  141:1467-1468. 2005
    2005 A randomized controlled trial assessing the efficacy of fluconazole in the treatment of pediatric tinea capitis.Journal of The American Academy of Dermatology.  53:798-809. 2005
    2005 Modification of the Nail Psoriasis Severity Index.Journal of The American Academy of Dermatology.  53:745-746. 2005
    2004 Comparison of 15% azelaic acid gel and 0.75% metronidazole gel for the topical treatment of papulopustular rosacea.Archives of Dermatology -Chicago-.  140:1282-1283. 2004
    2004 BioterrorismDermatologic Clinics.  22. 2004
    2004 Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002.Journal of The American Academy of Dermatology.  50:748-752. 2004
    2004 The use of 40% urea cream in the treatment of moccasin tinea pedis.Cutis.  73:355-357. 2004
    2004 Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association "Administrative Regulations for Evidence-Based Clinical Practice Guidelines".Journal of The American Academy of Dermatology.  50:391-404. 2004
    2004 Onychotillomania: 2 case reports.Cutis.  73:171-174. 2004
    2003 A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial.Archives of Dermatology -Chicago-.  139:1444-1450. 2003
    2003 Tinea capitis in adult women masquerading as bacterial pyodermaJournal of The American Academy of Dermatology.  49:177-179. 2003
    2003 Tinea capitis in adult women masquerading as bacterial pyoderma.Journal of The American Academy of Dermatology.  49:S177-S179. 2003
    2003 Tinea corporis, tinea cruris, tinea nigra, and piedra.Dermatologic Clinics.  21:395-v. 2003
    2003 Tinea capitis in Cleveland: survey of elementary school students.Journal of The American Academy of Dermatology.  48:189-193. 2003
    2002 Cutaneous anthrax management algorithm.Journal of The American Academy of Dermatology.  47:766-769. 2002
    2002 Infliximab for the treatment of severe pustular psoriasis.Journal of The American Academy of Dermatology.  47:796-797. 2002
    2002 Office practice-based confirmation of onychomycosis: a US nationwide prospective survey.Archives of Internal Medicine -New Series-.  162:2133-2138. 2002
    2002 Extrafacial and generalized granulomatous periorificial dermatitis.Archives of Dermatology -Chicago-.  138:1354-1358. 2002
    2002 The diagnosis and treatment of nail disorders: Systemic antifungal therapyDermatologic Therapy.  15:78-88. 2002
    2002 Reactivity to trichophytin antigen in patients with onychomycosis: effect of terbinafine.Journal of The American Academy of Dermatology.  46:371-375. 2002
    2002 Cutaneous fungal infections in the elderly.Clinics in Geriatric Medicine.  18:59-75. 2002
    2001 Efficacy and safety of terbinafine 1% solution in the treatment of interdigital tinea pedis and tinea corporis or tinea crurisCutis.  67:261-266. 2001
    2001 Guidelines of care for liposuction.Journal of The American Academy of Dermatology.  45:438-447. 2001
    2001 Tinea capitis of childhood: incidence and pathogenetic role of Trichophyton tonsurans in Central Europe.Journal of The American Academy of Dermatology.  45:320-321. 2001
    2001 The safety and efficacy of terbinafine in patients with diabetes and patients who are HIV positive.Cutis.  68:23-29. 2001
    2001 Itraconazole pulse therapy is effective and well-tolerated for the treatment of mycotic skin diseaseTodays Therapeutic Trends.  19:1-8. 2001
    2000 Drug-induced photosensitivity with antimycotics.Journal of the European Academy of Dermatology and Venereology.  14:444. 2000
    2000 A novel treatment for acne vulgaris and rosacea.Journal of the European Academy of Dermatology and Venereology.  14:423-424. 2000
    2000 The diagnosis of nail fungus infection revisited.Archives of Dermatology -Chicago-.  136:1162-1164. 2000
    2000 Sex-based professional societies are by no means obsolete--yet.Archives of Dermatology -Chicago-.  136:553. 2000
    2000 A large-scale North American study of fungal isolates from nails: The frequency of onychomycosis, fungal distribution, and antifungal susceptibility patternsJournal of The American Academy of Dermatology.  43:641-648. 2000
    2000 Antifungal drug interactions. Avoidance requires more than memorization.Postgraduate Medicine.  107:41-43. 2000
    2000 Erratum: Tinea capitis: A current perspective (Journal of the American Academy of Dermatology (January 2000) 42 (1-20))Journal of The American Academy of Dermatology.  42:704. 2000
    2000 New developments in cutaneous fungal infectionsCurrent Problems in Dermatology -Chicago then St Louis-.  12:81-85. 2000
    2000 Onychomycosis. Treatment, quality of life, and economic issues.American Journal of Clinical Dermatology.  1:19-26. 2000
    2000 Tinea capitis : a current perspectiveJ Am Acad Dermatol.  42. 2000
    2000 Tinea capitis: a current perspective.Journal of The American Academy of Dermatology.  42:1-20. 2000
    2000 Tinea capitis: a current perspective.Journal of The American Academy of Dermatology.  42:1-20. 2000
    1999 Antifungal susceptibilities and genetic relatedness of serial Trichophyton rubrum isolates from patients with onychomycosis of the toenail.Mycoses.  42 Suppl 2:105-110. 1999
    1999 Successful treatment of fluconazole-resistant oropharyngeal candidiasis by a combination of fluconazole and terbinafine.Clinical and Diagnostic Laboratory Immunology.  6:921-923. 1999
    1999 A full "cure" for onychomycosis is not always possible.Archives of Dermatology -Chicago-.  135:852-853. 1999
    1999 Safety of itraconazole pulse therapy for onychomycosis. An update.Postgraduate Medicine.  Spec No:17-25. 1999
    1999 Update on superficial fungal infections. Introduction.Postgraduate Medicine.  Spec No:5. 1999
    1999 Novel treatment strategies for superficial mycoses: introduction.Journal of The American Academy of Dermatology.  40:S1-S2. 1999
    1999 Optimal growth conditions for the determination of the antifungal susceptibility of three species of dermatophytes with the use of a microdilution method.Journal of The American Academy of Dermatology.  40:S9-13. 1999
    1999 Treatment of tinea capitis: beyond griseofulvin.Journal of The American Academy of Dermatology.  40:S27-S30. 1999
    1999 Asthma induced by allergy to Trichophyton rubrum.Journal of the European Academy of Dermatology and Venereology.  12:250-253. 1999
    1999 Antifungal susceptibilities and genetic relatedness of serial Trichophyton rubrum isolates from patients with onychomycosis of the toenail.Mycoses.  42 Suppl 2:105-110. 1999
    1999 British journal of dermatology: IntroductionBritish Journal of Dermatology -Supplement-.  141. 1999
    1999 Treatment of tinea pedis when bacterial presence is suspected: A review of the literatureTodays Therapeutic Trends.  17:159-165. 1999
    1998 Onychomycosis: pathogenesis, diagnosis, and management.Clinical Microbiology Reviews.  11:415-429. 1998
    1998 Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernailJournal of The American Academy of Dermatology.  38. 1998
    1998 Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenailJournal of The American Academy of Dermatology.  38. 1998
    1998 Once-weekly fluconazole in the treatment of onychomycosis: IntroductionJournal of The American Academy of Dermatology.  38. 1998
    1998 Pharmacokinetics of three doses of once-weekly fluconazole (150, 300, and 450 mg) in distal subungual onychomycosis of the toenailJournal of The American Academy of Dermatology.  38. 1998
    1998 Pharmacokinetics of three once-weekly dosages of fluconazole (150, 300, or 450 mg) in distal subungual onychomycosis of the fingernailJournal of The American Academy of Dermatology.  38. 1998
    1998 Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail.Journal of The American Academy of Dermatology.  38:S87-S94. 1998
    1998 Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail.Journal of The American Academy of Dermatology.  38:S77-S86. 1998
    1998 Once-weekly fluconazole in the treatment of onychomycosis: introduction.Journal of The American Academy of Dermatology.  38:S73-S76. 1998
    1998 Pharmacokinetics of three doses of once-weekly fluconazole (150, 300, and 450 mg) in distal subungual onychomycosis of the toenail.Journal of The American Academy of Dermatology.  38:S103-S109. 1998
    1998 Pharmacokinetics of three once-weekly dosages of fluconazole (150, 300, or 450 mg) in distal subungual onychomycosis of the fingernail.Journal of The American Academy of Dermatology.  38:S110-S116. 1998
    1998 Tinea capitis: fluconazole in Trichophyton tonsurans infection.Pediatric Dermatology.  15:229-232. 1998
    1997 A historical perspective on onychomycosisDermatologic Therapy.  3:43-45. 1997
    1997 Tinea capitis treatmentDermatologic Therapy.  3:79-83. 1997
    1997 Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial.Journal of The American Academy of Dermatology.  37:740-745. 1997
    1997 Trichophyton rubrum onychomycosis in a 17-year-old girl.Cutis.  60:253-254. 1997
    1997 Large-scale epidemiological study of the causal agents of onychomycosis: mycological findings from the Multicenter Onychomycosis Study of Terbinafine.Archives of Dermatology -Chicago-.  133:1317-1318. 1997
    1997 The effect of toenail onychomycosis on patient quality of life.International Journal of Dermatology.  36:754-756. 1997
    1997 Bacterial infection in a patient with onychomycosis.Journal of The American Academy of Dermatology.  37:493-494. 1997
    1997 Fungal infections in HIV-infected patients.Seminars in Cutaneous Medicine and Surgery.  16:200-212. 1997
    1997 Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions.Archives of Dermatology -Chicago-.  133:1172-1173. 1997
    1997 Treatment of tinea capitis with itraconazole.International Journal of Dermatology.  36:539-541. 1997
    1997 Cardiac arrhythmias associated with coadministration of azole compounds and cisapride.Clinical Infectious Diseases.  24:1285. 1997
    1997 A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: a multicentre study.British Journal of Dermatology.  136:786-789. 1997
    1997 Proposed guidelines for speakers discussing medications and other products.Cutis.  59:271-272. 1997
    1997 Double-blind, randomized comparison of itraconazole capsules vs. placebo in the treatment of toenail onychomycosis.Cutis.  59:217-220. 1997
    1997 Superficial fungal infections. Errors to avoid in diagnosis and treatment.Postgraduate Medicine.  101:279-287. 1997
    1997 Onychomycosis in children: prevalence and treatment strategies.Journal of The American Academy of Dermatology.  36:395-402. 1997
    1997 A multicenter, placebo-controlled, double-blind study of intermittent therapy with itraconazole for the treatment of onychomycosis of the fingernail.Journal of The American Academy of Dermatology.  36:231-235. 1997
    1997 One-week therapy with twice-daily butenafine 1% cream versus vehicle in the treatment of tinea pedis: a multicenter, double-blind trial.Journal of The American Academy of Dermatology.  36:S15-S19. 1997
    1997 Treatment of interdigital tinea pedis with a 4-week once-daily regimen of butenafine hydrochloride 1% cream.Journal of The American Academy of Dermatology.  36:S9-14. 1997
    1997 Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trialJournal of The American Academy of Dermatology.  37:740-745. 1997
    1997 The use of itraconazole in the treatment of superficial and systemic fungal infectionsTodays Therapeutic Trends.  14:207-224. 1997
    1996 Diagnostic techniques for confirming onychomycosisJournal of The American Academy of Dermatology.  35. 1996
    1996 Intermittent fluconazole dosing in patients with onychomycosis: Results of a pilot studyJournal of The American Academy of Dermatology.  35:216-219. 1996
    1996 Nondermatophyte causes of onychomycosis and superficial mycoses.Current topics in medical mycology.  7:87-97. 1996
    1996 A U.S. epidemiologic survey of superficial fungal diseases.Journal of The American Academy of Dermatology.  35:539-542. 1996
    1996 Comparison of an antifungal agent used alone with an antifungal used with a topical steroid in inflammatory tinea pedis.Cutis.  58:305-307. 1996
    1996 Diagnostic techniques for confirming onychomycosis.Journal of The American Academy of Dermatology.  35:S6-S9. 1996
    1996 Restructuring dermatology education at Cleveland medical centers affiliated with Case Western Reserve University.Archives of Dermatology -Chicago-.  132:1085-1090. 1996
    1996 Intermittent fluconazole dosing in patients with onychomycosis: results of a pilot study.Journal of The American Academy of Dermatology.  35:216-219. 1996
    1996 Onychomycosis caused by Scytalidium dimidiatum.Journal of The American Academy of Dermatology.  35:336-338. 1996
    1996 Thrombocytopenia caused by fluconazole.Journal of The American Academy of Dermatology.  35:284. 1996
    1996 Update on the management of onychomycosis: highlights of the Third Annual International Summit on Cutaneous Antifungal Therapy.Clinical Infectious Diseases.  23:305-313. 1996
    1996 Cutaneous lesions provide a clue to mysterious pulmonary process. Pulmonary and cutaneous North American blastomycosis infection.Archives of Dermatology -Chicago-.  132:822-825. 1996
    1996 Cutaneous lesions provide a clue to mysterious pulmonary process. Pulmonary and cutaneous North American blastomycosis infection.Archives of Dermatology -Chicago-.  132. 1996
    1996 Systemic antifungal drugs and drug interactions.Journal of The American Academy of Dermatology.  35:134-135. 1996
    1996 Widespread papules and nodules in a Ugandan man with acquired immunodeficiency syndrome. African blastomycosis.Archives of Dermatology -Chicago-.  132:821-824. 1996
    1996 Cutaneous mycoses in children.British Journal of Dermatology.  134 Suppl 46:7-11: discussion 37-8. 1996
    1996 Surgical pearl: Nail micronizerJournal of The American Academy of Dermatology.  34:278. 1996
    1996 Clinical pearl: diagnostic procedures for tinea capitis.Journal of The American Academy of Dermatology.  34:498-499. 1996
    1996 Guidelines of care for superficial mycotic infections of the skin: Pityriasis (tinea) versicolor. Guidelines/Outcomes Committee. American Academy of Dermatology.Journal of The American Academy of Dermatology.  34:287-289. 1996
    1996 Guidelines of care for superficial mycotic infections of the skin: tinea capitis and tinea barbae. Guidelines/Outcomes Committee. American Academy of Dermatology.Journal of The American Academy of Dermatology.  34:290-294. 1996
    1996 Guidelines of care for superficial mycotic infections of the skin: tinea corporis, tinea cruris, tinea faciei, tinea manuum, and tinea pedis. Guidelines/Outcomes Committee. American Academy of Dermatology.Journal of The American Academy of Dermatology.  34:282-286. 1996
    1996 Surgical pearl: nail micronizer.Journal of The American Academy of Dermatology.  34:278. 1996
    1996 Cutaneous antifungal therapy in AIDS: Summary of an International SummitInfectious Diseases in Clinical Practice.  5:359-370. 1996
    1996 Guidelines of care for superficial mycotic infections of the skin: Piedra. Guidelines/Outcomes Committee. American Academy of Dermatology.Journal of The American Academy of Dermatology.  34:122-124. 1996
    1996 Guidelines of care for superficial mycotic infections of the skin: mucocutaneous candidiasis. Guidelines/Outcome Committee. American Academy of Dermatology.Journal of The American Academy of Dermatology.  34:110-115. 1996
    1996 Guidelines of care for superficial mycotic infections of the skin: onychomycosis. Guidelines/Outcomes Committee. American Academy of Dermatology.Journal of The American Academy of Dermatology.  34:116-121. 1996
    1996 International summit on cutaneous antifungal therapy, focus on tinea capitis, Boston, Massachusetts, November 11-13, 1994.Pediatric Dermatology.  13:69-77. 1996
    1996 Tinea capitis.Dermatologic Clinics.  14:23-31. 1996
    1995 Candida as a nail pathogen in healthy patients.Journal of the Mississippi State Medical Association.  36:379-381. 1995
    1995 Bonsai tree: risk factor for disseminated sporotrichosis.Journal of The American Academy of Dermatology.  33:839-840. 1995
    1995 Clinical pearl: systemic antifungal drugs and drug interactions.Journal of The American Academy of Dermatology.  33:259-260. 1995
    1995 Antifungal agents.Journal of The American Academy of Dermatology.  32:1060-1061. 1995
    1995 Cost of therapy for dermatophyte infections.Journal of The American Academy of Dermatology.  32:1062. 1995
    1995 Failure of clotrimazole-betamethasone dipropionate cream in treatment of Microsporum canis infections.Journal of The American Academy of Dermatology.  32:1050-1051. 1995
    1995 Cutaneous involvement with Cryptococcus neoformans in AIDS.Journal of The American Academy of Dermatology.  32:820-821. 1995
    1995 Clinical pearl: diagnosis of onychomycosis.Journal of The American Academy of Dermatology.  32:500-501. 1995
    1995 Thrombocytopenia caused by fluconazole therapy.Journal of The American Academy of Dermatology.  32:525-526. 1995
    1995 Long-term outcome of patients with interdigital tinea pedis treated with terbinafine or clotrimazole.Journal of The American Academy of Dermatology.  32:290-292. 1995
    1995 Zosteriform zygomycosis.Journal of The American Academy of Dermatology.  32:357-361. 1995
    1995 ReplyJournal of The American Academy of Dermatology.  32:821. 1995
    1995 Trends in the Management of Cutaneous Fungal InfectionsJapanese Journal of Medical Mycology.  36:7-12. 1995
    1994 Tinea capitis: itraconazole in Trichophyton tonsurans infection.Journal of The American Academy of Dermatology.  31:65-67. 1994
    1994 Dermatophytes as opportunistic pathogens.Journal of The American Academy of Dermatology.  30:1021-1022. 1994
    1994 Cutaneous involvement with Cryptococcus neoformans in AIDS.Journal of The American Academy of Dermatology.  30:844-848. 1994
    1994 Short-duration therapy for superficial tinea infections.American Family Physician.  49:1349-1350. 1994
    1994 Introduction: International Summit on Cutaneous Antifungal TherapyJournal of The American Academy of Dermatology.  31:S1. 1994
    1993 Therapy of sporotrichosis.Seminars in dermatology.  12:285-289. 1993
    1993 Clinical pearl: proximal white subungual onychomycosis in AIDS.Journal of The American Academy of Dermatology.  29:631-632. 1993
    1993 Malignant fibrous histiocytoma resembling mycetoma.Journal of The American Academy of Dermatology.  29:318-321. 1993
    1993 Mechanisms of action of systemic antifungal agents.Journal of The American Academy of Dermatology.  28:S28-S34. 1993
    1993 Malignant fibrous histiocytoma resembling mycetomaJournal of The American Academy of Dermatology.  29:318-321. 1993
    1993 Mechanisms of action of systemic antifungal agentsJournal of The American Academy of Dermatology.  28:S28-S34. 1993
    1992 Cutaneous blastomycosis.Cutis.  50:422-424. 1992
    1992 Pyostomatitis vegetans and primary sclerosing cholangitis: markers of inflammatory bowel disease.Gastroenterology.  103:668-674. 1992
    1991 Hendersonula toruloidea and Scytalidium hyalinum. Review and update.Archives of Dermatology -Chicago-.  127:1041-1044. 1991
    1991 Rosacea-like lesions due to familial Mycobacterium avium-intracellulare infection.International Journal of Dermatology.  30:491-497. 1991
    1991 Childhood epidermolysis bullosa acquisita. Report of three cases and review of literature.Journal of The American Academy of Dermatology.  24:706-714. 1991
    1991 Pigmented postacne osteoma cutis in a patient treated with minocycline: report and review of the literature.Journal of The American Academy of Dermatology.  24:851-853. 1991
    1991 Childhood epidermolysis bullosa acquisita: Report of three cases and review of literatureJournal of The American Academy of Dermatology.  24:706-714. 1991
    1990 Does pityrosporum ovale have a role in psoriasis?Archives of Dermatology -Chicago-.  126:1111-1112. 1990
    1989 The superficial mycoses and the dermatophytes.Journal of The American Academy of Dermatology.  21:655-673. 1989
    1989 The superficial mycoses and the dermatophytes.Journal of The American Academy of Dermatology.  21:655-673. 1989
    1986 Reply to Dr. HoldinessInternational Journal of Dermatology.  25:406-406. 1986
    1985 Eruptive lesions and malignancy.International Journal of Dermatology.  24:617-629. 1985
    1985 Eruptive Lesions and MalignancyInternational Journal of Dermatology.  24:617-629. 1985
    1983 In vivo suppression of neutrophil chemotaxis by systemically and topically administered tetracycline.Journal of The American Academy of Dermatology.  8:807-812. 1983

    Chapter

    Year Title Altmetric
    2018 Systemic antifungals.  425-450. 2018
    2014 Tinea Barbae.  67-70. 2014
    2005 Onychomycosis.  123-131. 2005

    Research Overview

  • Dr. Boni Elewski’s research is aimed at developing new and innovative methods to diagnose and manage cutaneous fungal infections caused by dermatophyte fungi, as well as to establish their prevalence in certain populations. For example, she has determined that these common skin infections are increasing in prevalence at alarming rates and are particularly common in those immunocompromised by disease (HIV) or therapy (transplant recipients). Finding that tinea capitis (scalp ringworm) occurs in about 14% of children in Ohio, a four-fold increase in the past decade, Dr. Elewski is currently determining the prevalence of tinea capitis in Alabama and looking for links with other conditions, such as asthma and attention deficit disorder, that have also increased in prevalence in recent years. She also found that onychomycosis (nail fungus) occurs in 13% of the US population, a five fold increase over the last 50 years. Although effective antimycotic agents are available for treatment of these conditions, they continue to remain a diagnostic dilemma, and there is no simple diagnostic tool. Consequently, Dr. Elewski co-founded a dermatomycology laboratory at UAB to further study diagnosis and identification of these common infections. Dr. Elewski has also investigated the treatment of cutaneous fungal infections. Her work includes pivotal clinical studies on their management in children and adults. Additionally, Dr. Elewski found that immunologic response to fungal antigens or proteins is a predictor of treatment outcome. Her research is done through clinical trials, and the newly created UAB Fungal Reference Laboratory.
  • Principal Investigator On

  • Private Grant  awarded by LEO PHARMA 2019 - 2024
  • Private Grant  awarded by VALEANT PHARMACEUTICALS NORTH AMERICA LLC 2018 - 2023
  • Private Grant  awarded by ELI LILLY AND COMPANY 2018 - 2023
  • Private Grant  awarded by MENLO THERAPEUTICS INC 2018 - 2023
  • Private Grant  awarded by Procter & Gamble Company 2018 - 2023
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2018 - 2023
  • Private Grant  awarded by ANAPTYSBIO INC. 2018 - 2023
  • Private Grant  awarded by LILLY USA, LLC 2018 - 2023
  • Private Grant  awarded by MENLO THERAPEUTICS INC 2018 - 2023
  • Private Grant  awarded by VANDA PHARMACEUTICALS INC. 2018 - 2023
  • Private Grant  awarded by INFLARX GMBH 2018 - 2023
  • Private Grant  awarded by ELI LILLY AND COMPANY 2018 - 2023
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2017 - 2023
  • Private Grant  awarded by LEO PHARMA 2018 - 2023
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2017 - 2022
  • Private Grant  awarded by REGENERON PHARMACEUTICALS, INC. 2017 - 2022
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2018 - 2022
  • Private Grant  awarded by INCYTE CORPORATION 2017 - 2022
  • Private Grant  awarded by CELGENE CORPORATION 2017 - 2022
  • Private Grant  awarded by INCYTE CORPORATION 2017 - 2022
  • Private Grant  awarded by ABBVIE INC 2017 - 2022
  • Private Grant  awarded by ELI LILLY AND COMPANY 2017 - 2022
  • Private Grant  awarded by Pfizer Pharmaceuticals 2017 - 2022
  • Private Grant  awarded by ALLERGAN SALES, LLC 2017 - 2022
  • Private Grant  awarded by VALEANT PHARMACEUTICALS INTERNATIONAL 2016 - 2021
  • Private Grant  awarded by JANSSEN PHARMACEUTICALS PRODUCTS LP 2008 - 2021
  • Private Grant  awarded by INCYTE CORPORATION 2016 - 2021
  • Private Grant  awarded by NOVAN, INC. 2016 - 2021
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2016 - 2021
  • Private Grant  awarded by VALEANT PHARMACEUTICALS INTERNATIONAL 2015 - 2020
  • Private Grant  awarded by CELGENE CORPORATION 2015 - 2020
  • Private Grant  awarded by REGENERON PHARMACEUTICALS, INC. 2015 - 2020
  • Private Grant  awarded by VIAMET PHARMACEUTICALS, INC. - NEW 2015 - 2020
  • Private Grant  awarded by VALEANT PHARMACEUTICALS INTERNATIONAL 2015 - 2020
  • Private Grant  awarded by MERCK & COMPANY, INC. 2013 - 2019
  • Private Grant  awarded by ELI LILLY AND COMPANY 2012 - 2019
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2016 - 2019
  • Private Grant  awarded by Janssen Biotech, Inc. 2018 - 2019
  • Private Grant  awarded by ABBVIE INC 2018 - 2019
  • Private Grant  awarded by DUSA PHARMACEUTICALS, INC. 2015 - 2019
  • Private Grant  awarded by Pfizer Pharmaceuticals 2011 - 2019
  • Private Grant  awarded by Janssen 2015 - 2019
  • Private Grant  awarded by Janssen Biotech, Inc. 2017 - 2018
  • Private Grant  awarded by ABBVIE INC 2017 - 2018
  • Private Grant  awarded by Novartis Pharma AG 2012 - 2018
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2013 - 2018
  • Private Grant  awarded by ABBVIE INC 2016 - 2017
  • Private Grant  awarded by Janssen Biotech, Inc. 2016 - 2017
  • Private Grant  awarded by VALEANT PHARMACEUTICALS INTERNATIONAL 2015 - 2017
  • Private Grant  awarded by Janssen 2015 - 2016
  • Private Grant  awarded by Janssen Biotech, Inc. 2015 - 2016
  • Private Grant  awarded by ABBVIE INC 2015 - 2016
  • Fellowship Sponsorship/Grant  awarded by HAMAD MEDICAL CORPORATION 2011 - 2016
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2009 - 2016
  • Private Grant  awarded by AMGEN, INC. 2012 - 2016
  • Private Grant  awarded by MEIJI SEIKA PHARMA CO LTD - NEW 2014 - 2015
  • Private Grant  awarded by XENOPORT, INC. 2014 - 2015
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2015
  • Private Grant  awarded by ABBVIE INC 2014 - 2015
  • Private Grant  awarded by Janssen Biotech, Inc. 2014 - 2015
  • Private Grant  awarded by ABBVIE INC 2014 - 2015
  • Private Grant  awarded by Janssen Biotech, Inc. 2013 - 2014
  • Private Grant  awarded by REGENERON PHARMACEUTICALS, INC. 2013 - 2014
  • Private Grant  awarded by INTENDIS, INC. 2012 - 2014
  • Private Grant  awarded by STIEFEL LABORATORIES, INC. 2013 - 2014
  • Private Grant  awarded by VIAMET PHARMACEUTICALS, INC. - NEW 2013 - 2014
  • Private Grant  awarded by ABBVIE INC 2013 - 2014
  • Private Grant  awarded by ASUBIO PHARMACEUTICALS, INC. 2013 - 2014
  • Private Grant  awarded by CELGENE CORPORATION 2012 - 2014
  • Private Grant  awarded by NOVEN PHARMACEUTICAL, INC. 2011 - 2013
  • Private Grant  awarded by GALDERMA RESEARCH AND DEVELOPMENT, INC. 2010 - 2013
  • Private Grant  awarded by Centocor 2010 - 2013
  • Private Grant  awarded by Genentech 2006 - 2013
  • Private Grant  awarded by Centocor 2004 - 2013
  • Private Grant  awarded by Pfizer Pharmaceuticals 2011 - 2013
  • Private Grant  awarded by Centocor 2012 - 2013
  • Private Grant  awarded by Bayer HealthCare 2013
  • Private Grant  awarded by Janssen 2013
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2011 - 2013
  • Private Grant  awarded by GALDERMA RESEARCH AND DEVELOPMENT, INC. 2012 - 2013
  • Private Grant  awarded by ABBOTT LABORATORIES 2012 - 2013
  • Private Grant  awarded by JANSSEN PHARMACEUTICALS PRODUCTS LP 2012 - 2013
  • Private Grant  awarded by ANACOR PHARMACEUTICALS 2011 - 2013
  • Private Grant  awarded by CUTERA, INC. 2011 - 2013
  • Private Grant  awarded by AMGEN, INC. 2006 - 2013
  • Private Grant  awarded by MARUHO CO, LTD 2011 - 2013
  • Private Grant  awarded by Centocor 2006 - 2013
  • Private Grant  awarded by QUINNOVA 2011 - 2012
  • Private Grant  awarded by NITRIC BIOTHERAPEUTICS, INC. 2010 - 2012
  • Private Grant  awarded by STIEFEL LABORATORIES, INC. 2008 - 2012
  • Private Grant  awarded by ASTELLAS PHARMA US, INC. 2011 - 2012
  • Private Grant  awarded by ABBOTT LABORATORIES 2011 - 2012
  • Private Grant  awarded by Centocor 2011 - 2012
  • Private Grant  awarded by DOW PHARMACEUTICAL SCIENCES 2010 - 2011
  • Private Grant  awarded by NOVO NORDISK PHARMACEUTICALS, INC. 2009 - 2011
  • Private Grant  awarded by ABBOTT LABORATORIES 2008 - 2011
  • Private Grant  awarded by AMGEN, INC. 2007 - 2011
  • Private Grant  awarded by AMGEN, INC. 2009 - 2011
  • Dermatology Research Fellowship 2010-2011  awarded by National Psoriasis Foundation 2010 - 2011
  • Private Grant  awarded by Centocor 2010 - 2011
  • Private Grant  awarded by SCHERING PLOUGH CORPORATION 2010 - 2011
  • Private Grant  awarded by INTENDIS, INC. 2010 - 2011
  • Private Grant  awarded by DEPOMED, INC. 2008 - 2010
  • Private Grant  awarded by JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, LLC 2008 - 2010
  • Private Grant  awarded by STIEFEL LABORATORIES, INC. 2008 - 2010
  • Investigator On

  • Private Grant  awarded by AMGEN, INC. 2010 - 2012
  • Education And Training

  • Doctor of Medicine, Ohio State University System : Columbus
  • University of North Carolina Hospital, Residency 1982
  • Full Name

  • Boni Elewski
  • Blazerid

  • belewski